InvestorsHub Logo
Followers 37
Posts 6629
Boards Moderated 3
Alias Born 05/06/2014

Re: fulleroots post# 87269

Sunday, 08/09/2015 12:28:55 PM

Sunday, August 09, 2015 12:28:55 PM

Post# of 92948
Right. By no means are they undervalued. March financials show that OCATA has no book value (will be a little improved for June, because of dilution). They are at least 5 years away for a Macular Degeneration product. From a financial point of view, the price should be lower. OCATA is at this price level because of their science, that may or may not get to phase 4 completion. Larger and more powerful companies may develop a better method eventually, and move quicker to develop the method, since they will have the resources and influence( and better management).Just IMO.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.